In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Novo Nordisk (NVO) said its popular diabetes ... and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. The Danish drugmaker said the approval makes ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Sending letters to encourage guideline-directed practice in the management of chronic kidney disease to either patients or ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Novo Nordisk A/S NVO shares lost 2.7% on ... Ozempic is also indicated for treating chronic kidney disease and Wegovy received FDA approval last year to reduce the risk of heart disease.

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...